Eosinophilic granulomatosis with polyangiitis
AstraZeneca Secures FDA Approval for Fasenra in Rare Autoimmune Disorder EGPA
AstraZeneca, Fasenra, FDA approval, EGPA, rare autoimmune disorder, asthma biologic
AstraZeneca’s Fasenra Gains FDA Approval for Eosinophilic Granulomatosis with Polyangiitis, Expanding Treatment Options for Rare Autoimmune Disease
AstraZeneca, Fasenra, FDA approval, eosinophilic granulomatosis with polyangiitis (EGPA), rare autoimmune disease, biologic treatment, asthma medication, GSK’s Nucala